Heart rate control and its predictors in patients with heart failure and sinus rhythm. Data from the European Society of Cardiology Long-Term Registry.
acute heart failure
beta blocker
hospitalization
ivabradine
sinus rhythm
target heart rate
Journal
Cardiology journal
ISSN: 1898-018X
Titre abrégé: Cardiol J
Pays: Poland
ID NLM: 101392712
Informations de publication
Date de publication:
17 Aug 2022
17 Aug 2022
Historique:
received:
24
01
2022
accepted:
17
07
2022
revised:
04
07
2022
entrez:
17
8
2022
pubmed:
18
8
2022
medline:
18
8
2022
Statut:
aheadofprint
Résumé
Higher resting heart rate (HR) in patients with heart failure (HF) and sinus rhythm (SR) is associated with increased mortality. In patients hospitalized for HF, the aim herein, was to assess the use and dosage of guideline-recommended HR lowering medications, HR control at discharge and predictors of HR control. In the present study, were Polish participants of the European Society of Cardiology HF Long-Term (ESC-HF-LT) Registry. Those selected were hospitalized for HF, with reduced ejection fraction (HFrEF) and SR at discharge (n = 236). The patients were divided in two groups ( < 70 and ≥ 70 bpm). Logistic regression was used to identify the predictors of HR ≥ 70 bpm. Of patients with HFrEF and SR, 59% had HR ≥ 70 bpm at hospital discharge. At discharge, 96% and only 0.5% of the patients with HFrEF and SR received beta-blocker and ivabradine, respectively. In the HF groups < 70 and ≥ 70 bpm, only 11% and 4% of patients received beta-blocker target doses, respectively. There was no difference in the use of other guideline-recommended medications. Age, New York Heart Association class, HR on admission and lack of HR lowering medications were predictors of discharge HR ≥ 70 bpm. Heart rate control after hospitalization for HFrEF is unsatisfactory, which may be attributed to suboptimal doses of beta-blockers, and negligence in use other HR lowering drugs (including ivabradine).
Sections du résumé
BACKGROUND
BACKGROUND
Higher resting heart rate (HR) in patients with heart failure (HF) and sinus rhythm (SR) is associated with increased mortality. In patients hospitalized for HF, the aim herein, was to assess the use and dosage of guideline-recommended HR lowering medications, HR control at discharge and predictors of HR control.
METHODS
METHODS
In the present study, were Polish participants of the European Society of Cardiology HF Long-Term (ESC-HF-LT) Registry. Those selected were hospitalized for HF, with reduced ejection fraction (HFrEF) and SR at discharge (n = 236). The patients were divided in two groups ( < 70 and ≥ 70 bpm). Logistic regression was used to identify the predictors of HR ≥ 70 bpm.
RESULTS
RESULTS
Of patients with HFrEF and SR, 59% had HR ≥ 70 bpm at hospital discharge. At discharge, 96% and only 0.5% of the patients with HFrEF and SR received beta-blocker and ivabradine, respectively. In the HF groups < 70 and ≥ 70 bpm, only 11% and 4% of patients received beta-blocker target doses, respectively. There was no difference in the use of other guideline-recommended medications. Age, New York Heart Association class, HR on admission and lack of HR lowering medications were predictors of discharge HR ≥ 70 bpm.
CONCLUSIONS
CONCLUSIONS
Heart rate control after hospitalization for HFrEF is unsatisfactory, which may be attributed to suboptimal doses of beta-blockers, and negligence in use other HR lowering drugs (including ivabradine).
Identifiants
pubmed: 35975794
pii: VM/OJS/J/88117
doi: 10.5603/CJ.a2022.0076
pmc: PMC10713215
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Pol Arch Intern Med. 2018 Nov 30;128(11):649-657
pubmed: 30303491
Pol Arch Intern Med. 2017 Oct 31;127(10):657-665
pubmed: 28786405
Eur J Heart Fail. 2015 Nov;17(11):1182-91
pubmed: 26358762
Am J Cardiol. 2016 Mar 15;117(6):946-51
pubmed: 26805662
Circulation. 2012 Jul 24;126(4):501-6
pubmed: 22825412
Eur Heart J. 2012 Nov;33(22):2813-20
pubmed: 22927555
Clin Res Cardiol. 2013 Jan;102(1):23-31
pubmed: 22760479
Eur J Heart Fail. 2010 Oct;12(10):1076-84
pubmed: 20805094
Cardiol J. 2020;27(6):857-867
pubmed: 30799548
Cardiol J. 2014;21(4):425-33
pubmed: 24142684
Int J Cardiol. 2014 Dec 15;177(2):380-4
pubmed: 25189497
Eur J Med Res. 2020 Oct 8;25(1):47
pubmed: 33032633
J Am Heart Assoc. 2015 Apr 22;4(4):
pubmed: 25904590
Cardiol J. 2020;27(6):904-905
pubmed: 33432572
Ann Intern Med. 2009 Jun 2;150(11):784-94
pubmed: 19487713
J Cardiol. 2012 Aug;60(2):86-90
pubmed: 22920717
N Engl J Med. 1996 May 23;334(21):1349-55
pubmed: 8614419
Cardiol J. 2022;29(6):1013-1019
pubmed: 34308538
Kardiol Pol. 2021;79(9):980-987
pubmed: 34227675
Eur J Heart Fail. 2019 Apr;21(4):471-479
pubmed: 30698317
Eur Heart J. 2020 Dec 7;41(46):4415-4422
pubmed: 33211823
Lancet. 2010 Sep 11;376(9744):875-85
pubmed: 20801500
Lancet. 2010 Sep 11;376(9744):886-94
pubmed: 20801495
J Am Coll Cardiol. 2012 May 29;59(22):1938-45
pubmed: 22617188
Am J Cardiol. 2020 Mar 15;125(6):894-900
pubmed: 31980141
JACC Heart Fail. 2013 Dec;1(6):488-96
pubmed: 24622000
Eur J Heart Fail. 2016 Jun;18(6):613-25
pubmed: 27324686
Pol Arch Intern Med. 2019 Feb 28;129(2):106-116
pubmed: 30648697
N Engl J Med. 2001 May 31;344(22):1651-8
pubmed: 11386263
J Am Coll Cardiol. 2001 May;37(6):1692-9
pubmed: 11345386
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
J Clin Diagn Res. 2014 Aug;8(8):BE01-4
pubmed: 25302188
Circulation. 2018 Jul 3;138(1):80-98
pubmed: 29967232
Rev Esp Cardiol (Engl Ed). 2015 Sep;68(9):785-93
pubmed: 26003504